Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DFP-14927 by Delta-Fly Pharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
DFP-14927 is under clinical development by Delta-Fly Pharma and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
DFP-14927 by Delta-Fly Pharma for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
DFP-14927 is under clinical development by Delta-Fly Pharma and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
DFP-14927 by Delta-Fly Pharma for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
DFP-14927 is under clinical development by Delta-Fly Pharma and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
DFP-14927 by Delta-Fly Pharma for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
DFP-14927 is under clinical development by Delta-Fly Pharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...
DFP-14927 by Delta-Fly Pharma for Solid Tumor: Likelihood of Approval
DFP-14927 is under clinical development by Delta-Fly Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
DFP-14927 by Delta-Fly Pharma for Pancreatic Cancer: Likelihood of Approval
DFP-14927 is under clinical development by Delta-Fly Pharma and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...